Thyroid eye disease (TED) therapy Tepezza – the top asset in Amgen's $26 billion takeover of Horizon in 2023 – may very well be struggling with Levels of competition from A neater-to-dose alternate from Sling Therapeutics. Various unfavorable trials of insulin?like development iss